2026 Q3 Portfolio Activity
In 2026 Q3, Foresite Capital Management VI LLC maintained a portfolio of 27 distinct positions. The most significant new addition was Korsana Biosciences, Inc., now representing 8.09% of the total fund value. They heavily accumulated shares in ArriVent BioPharma, Inc., increasing the position by 62.7%. Conversely, Foresite Capital Management VI LLC completely exited their position in Celldex Therapeutics, Inc..
Position History
hover any row below to update
Loading…
Total Positions
27
Quarter
2026 Q3
Top Holding
CGON (26.4%)
Top 10 Concentration
77.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-27 of 27
Foresite Capital Management VI LLC Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CGON
CG Oncology, In...
|
Healthcare | 26.41% | 26.20% |
#1
Prev: #1
|
6.5 |
—
|
-260,000 | -11.0% |
P
S
|
2,109,574 | $149,547,701 |
$31.33
+152.0%
|
2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
KRSA
Korsana Bioscie...
|
Healthcare | 8.09% | — |
#2
Prev: #—
|
8.2 |
—
|
1,431,660 | — |
NEW
|
1,431,660 | $45,813,120 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
LTGO
Latigo Biothera...
|
Healthcare | 6.50% | — |
#3
Prev: #—
|
7.1 |
—
|
2,203,800 | — |
NEW
|
2,203,800 | $36,803,460 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
SPTX
Seaport Therape...
|
Healthcare | 6.34% | 6.02% |
#4
1
Prev: #3
|
4.0 |
—
|
no change | no change |
P
S
|
1,779,521 | $35,892,939 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
DNLI
Denali Therapeu...
|
Healthcare | 5.90% | 5.59% |
#5
1
Prev: #4
|
4.9 |
—
|
221,000 | 15.8% |
P
S
|
1,617,771 | $33,439,327 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
PBLS
Parabilis Medic...
|
Healthcare | 5.70% | 4.26% |
#6
2
Prev: #8
|
3.3 |
—
|
no change | no change |
P
S
|
999,044 | $32,259,131 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ALMS
ALUMIS INC.
|
Healthcare | 5.54% | 18.60% |
#7
5
Prev: #2
|
3.2 |
—
|
no change | no change |
P
S
|
4,247,670 | $31,390,281 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 4.86% | 4.53% |
#8
2
Prev: #6
|
3.9 |
—
|
42,128 | 5.4% |
P
S
|
827,128 | $27,502,006 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
VSTM
Verastem, Inc.
|
Healthcare | 4.47% | 1.87% |
#9
5
Prev: #14
|
2.8 |
—
|
no change | no change |
P
S
|
3,146,631 | $25,330,380 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
GHRS
GH Research PLC
|
Healthcare | 3.90% | 3.93% |
#10
1
Prev: #9
|
2.6 |
—
|
no change | no change |
P
S
|
940,493 | $22,082,776 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CRVS
Corvus Pharmace...
|
Healthcare | 3.72% | 4.26% |
#11
4
Prev: #7
|
2.5 |
—
|
no change | no change |
P
S
|
1,831,233 | $21,095,804 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KYMR
Kymera Therapeu...
|
Healthcare | 2.89% | 2.61% |
#12
Prev: #12
|
2.2 |
—
|
no change | no change |
P
S
|
146,332 | $16,358,454 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AVBP
ArriVent BioPha...
|
Healthcare | 2.62% | 1.63% |
#13
4
Prev: #17
|
4.0 |
—
|
189,000 | 62.7% |
P
S
|
490,341 | $14,847,525 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
OBX
Obsidian Therap...
|
Healthcare | 2.22% | — |
#14
Prev: #—
|
4.4 |
—
|
916,063 | — |
NEW
|
916,063 | $12,577,545 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
JBIO
Jade Bioscience...
|
Healthcare | 2.20% | 3.07% |
#15
5
Prev: #10
|
1.9 |
—
|
no change | no change |
P
S
|
886,667 | $12,457,671 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
HNGE
Hinge Health, I...
|
Healthcare | 1.86% | 2.85% |
#16
5
Prev: #11
|
0.7 |
—
|
-112,300 | -51.0% |
P
S
|
108,100 | $10,511,644 | 2025 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
AURA
Aura Bioscience...
|
Healthcare | 1.48% | 1.47% |
#17
1
Prev: #18
|
1.6 |
—
|
no change | no change |
P
S
|
1,333,334 | $8,373,338 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
BEAM
Beam Therapeuti...
|
Healthcare | 1.42% | 1.76% |
#18
3
Prev: #15
|
1.6 |
—
|
no change | no change |
P
S
|
330,000 | $8,068,500 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ZURA
Zura Bio Ltd
|
Healthcare | 1.29% | 0.41% |
#19
2
Prev: #21
|
3.5 |
—
|
1,307,000 | 290.4% |
P
S
|
1,757,000 | $7,309,120 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
NERV
Minerva Neurosc...
|
Healthcare | 1.17% | 1.71% |
#20
4
Prev: #16
|
1.5 |
—
|
no change | no change |
P
S
|
1,985,584 | $6,651,706 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
IRON
Disc Medicine, ...
|
Healthcare | 0.79% | 0.01% |
#21
2
Prev: #23
|
3.3 |
—
|
67,500 | 6958.8% |
P
S
|
68,470 | $4,482,046 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ENTX
Entera Bio Ltd.
|
Healthcare | 0.63% | — |
#22
Prev: #—
|
3.8 |
—
|
1,225,490 | — |
NEW
|
1,225,490 | $3,566,176 | 2026 Q3 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
KLRA
Kailera Therape...
|
Healthcare | 0.00% | 0.13% |
Sold All 😨
(Was: #22) |
0.0 |
—
|
-37,500 | -100.0% |
CLOSED
|
— | $— | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
N/A
Research Allian...
|
|
Unknown | 0.00% | 0.50% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-300,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-09-30 | 2026-11-16 | ||
|
CRNX
Crinetics Pharm...
|
Healthcare | 0.00% | 1.23% |
Sold All 😨
(Was: #19) |
0.0 |
—
|
-212,010 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
ATAI
AtaiBeckley Inc...
|
Healthcare | 0.00% | 2.26% |
Sold All 😨
(Was: #13) |
0.0 |
—
|
-2,750,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-16 | |||
|
CLDX
Celldex Therape...
|
Healthcare | 0.00% | 5.09% |
Sold All 😨
(Was: #5) |
0.0 |
—
|
-879,713 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-16 |
Showing 1-27 of 27 holdings